Crohn's and Colitis Congress 2022

Starting vedolizumab early after the diagnosis of ulcerative colitis (UC) appeared more effective than delaying it to after initiation of other UC treatments, according to the RALEE study.

Patients with inflammatory bowel disease (IBD) who have completed a COVID-19 vaccine regimen have a low risk of developing COVID-19, though receipt of mRNA vaccines may offer better protection, according to a small study presented at the Crohn’s and Colitis Congress 2022.

Partial enteral nutritional (PEN) therapy shows potential in the long-term management of mild paediatric Crohn’s disease, helping to avoid the use of corticosteroids and prevent side effects commonly observed with other inflammatory bowel disease therapies, according to a study presented at the virtual Crohn's & Colitis Congress.

Delays in endoscopies due to the coronavirus disease 2019 (COVID-19) pandemic does not seem to worsen clinical outcomes in patients with inflammatory bowel diseases (IBD), though healthcare utilization patterns appear to be affected, according to a study reported at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).

The addition of 5-aminosalicylic acid (5-ASA) to standard corticosteroid treatment did not improve outcomes in patients hospitalized with acute severe ulcerative colitis (UC), according to a study presented at the Crohn’s and Colitis Congress 2022.

The opinion that inflammatory bowel disease (IBD) is associated with poor sleep is not uncommon among patients with IBD, according to a study. Moreover, these individuals tend to think and behave in manners that worsen sleep and their disease.